Download PLAN TREAT TEST

TEST
TREAT
PLAN
In non-small cell lung cancer (NSCLC), planning can help
guide the appropriate treatment path for patients.
DIAGNOSE
An estimated
224,390
Out of those,
Of those with NSCLC,
will have
will be
or advanced
at diagnosis.2
57%
metastatic
~85%
new cases of lung cancer
are expected to be diagnosed
NSCLC.
2
in 2016.
1
TEST
Guidelines suggest certain patients should
have their tumors tested for biomarkers
in order to help identify what is driving
their lung cancer.3 There are currently
Estimated share of NSCLC patients
who have specific biomarkers:6
PIK3CA2
NRAS
MET
MEK1
ROS1
RET
PTEN
AKT
Unknown
ALK
BRAF
DDR2
known lung cancer
biomarkers.
KRAS
4, 5
EGFR
The majority of these biomarkers are
being studied in clinical trials; EGFR, ALK and
ROS1 are the only biomarkers associated with
FDA-approved biomarker driven therapy.
HER2
FGFR1
PLAN
Each journey is unique,
so patients and their care team should
work together to develop an
individualized treatment plan to guide
their journey. This may include testing
for certain biomarkers or discussing what
to expect with each treatment option.
TREAT
Currently there are
7 therapies
FDA-approved
associated with EGFR, ALK or ROS1
biomarkers,7 and more than 500
ongoing clinical trials involving
biomarkers in lung cancer.8
FOLLOW UP
Patients should continue to
work with their care team
to find out if their tumor is
responding to the medicine,
address any side effects, stay on
track with their treatment plan
and make adjustments as needed.
For additional resources, including a molecular testing glossary and patient-doctor conversation checklist,
visit www.LungCancerProfiles.com
References: 1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016. 2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Seer Stat Fact Sheets: Lung and Bronchus Cancer.
http://seer.cancer.gov/statfacts/html/lungb.html. Accessed October 5, 2015. 3. Lindeman N, Cagle P, Beasley M, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. J Thorac Oncol. 2013
Jul;8(7):823-59. 4. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011. 29(suppl;
abstr CRA7506). Page 10. http://meetinglibrary.asco.org/content/81670-102. Accessed September 1, 2015. 5. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nature. 2012;378-381. Doi:10.1038/nm.2558. 6. My Cancer
Genome. Molecular Profiling of Lung Cancer. 2015. http://www.mycancergenome.org/content/disease/lung-cancer/. Accessed January 22, 2015. 7. American Cancer Society. Targeted therapies for non-small cell lung cancer. http://www.cancer.org/
cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treating-targeted-therapies. March 8, 2016. 8. ClinicalTrials.gov. 524 studies found for: KRAS OR EGFR OR ALK OR PIK3CA OR HER2 OR BRAF OR ROS OR RET OR NRAS
OR MET | lung cancer. https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET&recr=Open&cond=lung+cancer&rcv_e=10%2
F14%2F2015 (Select “Include only open studies”). Accessed March 8, 2016.
This information is current as of April 2016.
© 2016 Pfizer Inc. All rights reserved. April 2016.
PP-XLK-USA-0244-01